For example, SB‐216763, an inhibitor of glycogen synthase kinase‐3β (GSK‐3β) and a pharmacological activator of the WNT/β‐catenin pathway, has been shown to suppress the ARVC phenotype in murine and zebrafish models [47, 48, 49]. This evidence concerns the gene GSK3B and arrhythmogenic right ventricular cardiomyopathy.